-transparent.png){kind=logo}
The authors analyze the treatment of 16 female infants with true precocious puberty, ages ranging from 12 months to 9.5 years at the time of diagnosis, based on clinical and laboratory findings. All patients were treated with 150 to 300 mg. every 15 to 20 days of injectable medroxyprogesterone acetate (MPA) for periods from 5 months to 6 years. The prognosis of the adult height was evaluated before and during MPA treatment using the following parameters: height velocity as a function of bone age (good response of 15 patients); height as a function of bone age (good response of 13 patients); developmental quotient (good response of 14 patients), and adult height prognosis by the use of the tables of Bayley & Pinneau (good response of 8 out of 10 patients). The authors conclude that MPA treatment was effective in improving the prognosis of adult height in 14 out of 16 patients of true precocious puberty.
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
September 1972,
Pediatrie,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
February 1965,
Proceedings of the Royal Society of Medicine,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
January 1972,
Padiatrie und Padologie,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
September 1970,
Minerva pediatrica,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
March 1976,
Minerva pediatrica,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
January 1983,
L'union medicale du Canada,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
May 1970,
The Journal of clinical endocrinology and metabolism,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
October 1964,
American journal of diseases of children (1960),
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
January 1966,
Revista do Hospital das Clinicas,
N Abodovsky, and
A Matus de la Parra, and
X Vivanco, and
E Onetto
January 1984,
Medicina,
